Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded down 6.4% on Monday . The stock traded as low as $13.72 and last traded at $13.96. 4,420,029 shares changed hands during mid-day trading, an increase of 57% from the average session volume of 2,808,526 shares. The stock had previously closed at $14.91.

Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Leerink Swann restated a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird restated an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a report on Monday, September 25th. Bank of America boosted their target price on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.81.

The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39. The stock has a market cap of $2,350.00, a PE ratio of -7.77 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.33) earnings per share. sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

In other Amicus Therapeutics news, Director Michael Raab sold 10,000 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $142,500.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the transaction, the chief executive officer now directly owns 393,076 shares in the company, valued at $5,310,456.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 826,114 shares of company stock worth $11,791,184. Company insiders own 3.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in Amicus Therapeutics in the 3rd quarter worth approximately $102,000. Tudor Investment Corp ET AL bought a new stake in shares of Amicus Therapeutics during the second quarter valued at approximately $124,000. Zacks Investment Management bought a new stake in shares of Amicus Therapeutics during the second quarter valued at approximately $145,000. Birchview Capital LP bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $151,000. Finally, Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $154,000.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics (FOLD) Stock Price Down 6.4%” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/10/amicus-therapeutics-fold-stock-price-down-6-4.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.